About the cover

Switching antiandrogen and abiraterone treatment



Metastatic castration-resistant prostate cancer (mCRPC) is the end stage of prostate cancer. Even in the era of novel targeted agents, the switching from one non-steroidal antiandrogen (NSAA) to another, as one of the earliest therapeutic strategies for mCRPC patients, is still widely used, especially for patients from medical-care undeveloped countries. It remains unknown whether the prior treatment with a second-line NSAA would impact the treatment efficacy of abiraterone. In this study, we found that the use of flutamide as a second-line NSAA before abiraterone has no adverse effect on the therapeutic efficacy of the sequential abiraterone treatment in mCRPC patients. Survival analyses indicated that regarding abiraterone treatment, patients firstly treated with second-line flutamide had almost the same PSA progression-free survival, radiographic progression-free survival, overall survival, and PSA response rate as those directly receiving abiraterone after being diagnosed with mCRPC. Please refer to pages 545-550 for details.

Feedback
Editorial board
Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal